Requirement for CD44 in activated T cell extravasation into an inflammatory site

Science

Volumn 278, Issue 5338, 1997, Pages 672-675

  DeGrendele, Heather C ^a   Estess, Pila ^a   Siegelman, Mark H ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN; HYALURONIC ACID; MONOCLONAL ANTIBODY; STAPHYLOCOCCUS ENTEROTOXIN B;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL INTERACTION; ENDOTHELIUM CELL; INFLAMMATION; LEUKOCYTE MIGRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD44; CELL ADHESION; CELL MOVEMENT; ENTEROTOXINS; HYALURONIC ACID; LIGANDS; LYMPH NODES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; PERITONEAL CAVITY; PERITONITIS; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; SUPERANTIGENS; T-LYMPHOCYTE SUBSETS;

ANIMALIA; MURINAE; STAPHYLOCOCCUS;

EID: 0030690228     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.278.5338.672     Document Type: Article

References (35)

1. C. R. Mackay, Immunol. Today 12, 189 (1991).
2. F. T. Koster and D. D. McGregor, J. Exp. Med. 133, 864 (1971).
3. G. D. Guy, C. Griscelli, P. Vassalli, ibid. 148, 1661 (1978).
4. T. B. Issekutz, J. Immunol. 147, 4178 (1991).
5. E. C. Butcher and L. J. Picker, Science 272, 60 1996).
6. T. A. Springer, Cell 76, 301 (1994).
7. J. Lesley, R. Hyman, P. W. Kincade, Adv. Immunol. 54, 271 (1993).
8. H. C. DeGrendele, P. Estess, L. J. Picker, M. H. Siegelman, J. Exp. Med. 183, 1119 (1996).
9. J. Lesley, N. Howes, A. Perschl, R. Hyman,ibid. 180, 383 (1994).
10. H. C. DeGrendele, P. Estess, M. H. Siegelman, J. Immunol. 159, 2549 (1997).
11. M. T. Scherer, L. Ignatowicz, G. M. Winslow, J. W. Kappler, P. Marrack, Annu. Rev. Cell Biol. 9, 101 (1993).
12. T. Hermann, S. Baschieri, R. K. Lees, H. R. MacDonald, Eur. J. Immunol. 22, 1935 (1992).
13. J. E. McCormack, J. E. Callahan, J. Kappler, P. C. Marrack, J. Immunol. 150, 3785 (1993).
14. J. Sprent, J. F. A. P. Miller, G. F. Mitchell, Cell. Immunol. 2, 171 (1971).
15. R. N. Cahill, H. Frost, Z. Trnka, J. Exp. Med. 143, 870 (1976).
16. J. Sprent, Cell 76, 315 (1994).
17. K. Miyake, C. B. Underhill, J. Lesley, P. W. Kincade, J. Exp. Med. 172, 69 (1990).
18. β14, anti-κ-FITC, and anti-FITC particles.
19. H. C. DeGrendele, P. Estess, M. H. Siegelman, data not shown.
20. 7 labeled cells per mouse in 0.5 ml of HBSS with or without the addition of blocking reagent. Depletions were done as above. Cells treated with whole antibody or Fab fragments were incubated in a saturating concentration of antibody for 15 min on ice and then washed before injection. HA and chondroitin sulfate (Sigma) were added to the cell suspension at the time of injection (final concentration, 0.5 μM). Hyaluronidase (ICN Biochemicals) and chondroitinase ABC (Sigma) treatment was done by injecting 10 U per mouse iv 30 min before donor cell infusion. Ninety minutes after the infusion of labeled cells, the recipient mice were killed and PELs were analyzed for the homing of labeled cells.
21. G. F. Weber, S. Ashkar, M. J. Glimcher, H. Cantor, Science 271, 509 (1996).
22. P. R. Maroko et al., N. Engl. J. Mod. 296, 898 (1977).
23. L. Szlavy, S. Kubik, A. deCourten, H. J. Hachen, F. Solti, Angiology 36, 452 (1985).
24. S. T. Jalkanen, R. F. Bargatze, L. R. Herron, E. C. Butcher, Eur. J. Immunol. 16, 1195 (1986).
25. S. Jalkanen, R. F. Bargatze, J. de los Toyos, E. C. Butcher, J. Cell Biol. 105, 983 (1987).
26. R. L. Camp, A. Scheynius, C. Johansson, E. Pure, J. Exp. Med. 178, 497 (1993).
27. K. Mikecz, F. R. Brennan, J. H. Kim, T. T. Glant, Nature Med. 1, 558 (1995).
28. B. F. Haynes, L. P. Hale, K. L. Patton, M. E. Martin, R. M. McCallum, Arthritis Rheum. 34, 1434 (1991).
29. A. Zeidler et al., Autoimmunity 21, 245 (1995).
30. M. Mohamadzadeh, H. C. DeGrendele, P. Estess, M. H. Siegelman, in preparation.
31. 3, and 0.1 mM EDTA. PELs were collected by peritoneal lavage using 5 ml of RPMI (37°C) containing 2% FBS and 2 mM EDTA. Staining of PELs was performed as above, except cells were preincubated with anti-CD32/CD16 (clone 2.4G2) and stained in the presence of 10% normal mouse serum to inhibit Fc receptor interactions. Data were collected on a FACScan analytical instrument (Becton Dickinson) and analyzed using Lysis II software.
32. A. N. de Belder and K. O. Wik, Carbohydr. Res. 44, 251 (1975).
33. 2) from outlet to inlet over a 4-min period.
34. R. Kennett, Monoclonal Antibodies (Plenum, New York, 1980).
35. We thank M. Kosfiszer for technical assistance and L. Picker for helpful discussions. Supported by grants from NIH (R01 CA57471 and HL56746), the Arthritis Foundation, and the Welch Foundation (I-1227). M.H.S. is an Established Investigator of the American Heart Association. H.C.D. is supported by an NIH Cancer Immunology Training Grant.